Project Grant HT94252310256

This National Science Foundation Project Grant of $649,998 will fund research into adaptive and regulatory diversity in natural CRISPR-Cas systems from March 1, 2023 to February 29, 2028. The grant was awarded under the Biological Sciences program (CFDA 47.074) to further the program's goals of advancing the biological sciences and strengthening the Nation's scientific enterprise. The University of Washington will investigate the mechanisms by which diverse CRISPR systems acquire immunological...

This five-year $385,645 Project Grant from the National Science Foundation's Biological Sciences program (CFDA 47.074) will fund research investigating RNA-guided nucleases encoded by transposons across the three domains of life. The grantee, Columbia University, will examine an ancestral family of transposon-encoded enzymes that use guide RNAs to target and cut matching DNA sequences. These enzymes are directly related to CRISPR-Cas9 and CRISPR-Cas12 genome editing tools. The project aims to...

This $1,000,000.00 Project Grant awarded by the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) supports research to characterize the molecular mechanisms by which the bridge helix (BH) region of the CRISPR-associated (Cas) 9 and Cas12a enzymes contributes to DNA cleavage fidelity. The overarching goal is to develop error-proof variants of these genome editing tools that minimize unintended off-target DNA modifications. The award includes a sub-grant to the University...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) provides $360,247 to Rutgers, The State University of New Jersey to conduct research on the molecular mechanisms of type III CRISPR-Cas systems in bacteria and archaea. The research aims to investigate how CRISPR-associated signaling effectors, including nucleases and membrane proteins, are regulated by cyclic nucleotide second...

This $509,070 Project Grant award from the National Science Foundation's Division of Molecular and Cellular Biosciences (CFDA 47.074 Biological Sciences) supports research at Purdue University to explore the working mechanism of CRISPR-Cas12 endonucleases and analogues. The primary goals are to investigate the regulatory mechanisms of natural CRISPR inhibitor proteins, and to dissect the structural dynamics of newly identified Cas12 analogues found in mobile genetic elements and viruses. This...

This $430,785 National Science Foundation (NSF) CAREER award to the Regents of the University of California at Riverside (UC Riverside), awarded under the NSF Engineering program (CFDA 47.041), is focused on developing novel CRISPR-based biosensing technologies for the ultra-accurate detection of disease-related single nucleotide polymorphisms (SNPs). The central goals of the 5-year project are to: 1) enable ultra-accurate SNP detection using a CRISPR-Cas14 biosensor, 2) design a ratiometric SNP...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $245,895.00 to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on using CRISPR-Cas9 base editing approaches to systematically identify ubiquitination events that promote flavivirus infection. The research aims to discover novel pathways that facilitate flavivirus infection and provide...

This Project Grant award from the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) provides $240,000 in funding to The Johns Hopkins University to explore the interactions between CRISPR-Cas immune systems and temperate bacteriophages. The project aims to understand how CRISPR-Cas systems, which protect bacteria from viral infections, can acquire memories about temperate phages that can enter a dormant "lysogenic" state within bacterial cells. The research...

This five-year Project Grant award of $200,016 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a non-viral genome editing therapy for Artemis-deficient severe combined immunodeficiency (ART-SCID). The principal investigator, Dr. Matthew Kan, a pediatric immunologist at the University of California, San Francisco (UCSF), will focus on establishing expertise in non-viral...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), aims to develop a microinjection-free approach for CRISPR/Cas-based genetic manipulation in the model organism C. elegans. The $398,774 award, spanning May 2025 to April 2027, will support research to efficiently deliver single-guide RNA (sgRNA) throughout C. elegans tissues via feeding, leveraging RNA carriers to facilitate...